跳至主要内容
临床试验/NCT01578122
NCT01578122已完成不适用

Evaluation of the Efficacy of Elastic Compression in Preventing Post-thrombotic Syndrome. Randomised Non-inferiority Study for Ankle Pressure Targeted at 25 mm Hg Versus 35 mm Hg

Laboratoires Innothera86 个研究点 分布在 1 个国家目标入组 350 人开始时间: 2012年6月29日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
350
试验地点
86
主要终点
To show that elastic compression with ankle pressure targeted at 25 mm Hg is not inferior in preventing the onset of clinical post-thrombotic syndrome to a target ankle pressure of 35 mm Hg (recommended pressure being greater than 30 mm Hg)

研究概览

简要总结

Post thrombotic syndrome (PTS) is a frequent and burdensome complication of proximal deep-vein thrombosis.Therapeutic options for PTS are limited and mainly rely on its prevention. Therapeutic trials evidenced that elastic compression stockings (ECS) applying 30-40mmHg of pressure at the ankle reduced the rate of PTS by 50%. Although ECS are unlikely to cause harm, in clinical practice, compliance to this treatment appears to be low as ECS may be difficult to apply and to wear.

ECS with a lighter compression strength (20-30mmHg) might be easier to apply and be more comfortable. This could favor a better compliance.

CELEST is a randomized, multicentre, double-blind trial which aims to determine whether ECS applying 25mmHg of targeted pressure at the ankle are non inferior to ECS applying 35mmHg of targeted pressure at the ankle

详细描述

CELEST trial is a controlled, randomized, multicentre, non-inferiority double-blind trial which aims to determine whether ECS applying 25mmHg of targeted pressure at the ankle are non inferior to ECS applying 35mmHg of targeted pressure at the ankle. Patients with a first acute symptomatic proximal DVT will be randomized to wear for two years either ECS applying 25mmHg of targeted pressure at the ankle or ECS applying 35mmHg of targeted pressure at the ankle. All patients will be prescribed anticoagulants for at least three months. The primary outcome will be the rate of PTS assessed with the Villalta scale in both arms of the study during the 2 years study period. Rate of compliance,severity of PTS and quality of life in both groups will constitute the main secondary outcomes.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Double (Participant, Investigator)

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • 未提供

排除标准

  • 未提供

结局指标

主要结局

To show that elastic compression with ankle pressure targeted at 25 mm Hg is not inferior in preventing the onset of clinical post-thrombotic syndrome to a target ankle pressure of 35 mm Hg (recommended pressure being greater than 30 mm Hg)

时间窗: 24 months

cumulative incidence 24 months after inclusion of PTS apparition defined by the Villalta score \> or equal to 5. A visual guide will be given to investigators to assist them and standardize PTS evaluation. Investigators will receive a Villalta training during set up visits.

次要结局

  • Superiority of 25 mm Hg on the therapeutic compliance criterion(24 months)
  • non inferiority of 25 mm Hg for the onset of permanent trophic disorders(3 months, 12 and 24 months)
  • test for key factors in good compliance(24 months)
  • superiority of targeted pressure at 35 mm Hg for compliant patients. Analysis of the primary endpoint per protocol amongst patients responding to the definition of compliance for compression scheduled by randomization(24 months)
  • non inferiority of 25 mm Hg for the intensity of long term chronic venous insufficiency symptoms (12 months and 24 months)(12 and 24 months)
  • non inferiority of 25 mm Hg for the onset of sequalae or post thrombotic residues on an duplex scan at 3 months, 12 and 24 months(3, 12 and 24 months)
  • Adverse events(24 months)
  • Subgroups analysis of the primary objective and secondary objectives according to the gender stratification criterion and age(24 months)
  • superiority of 25 mmHg on 35 mmHg in preventing the onset of clinical post thrombotic syndrome(24 months)
  • Non-inferiority of 25 mm Hg for changes in overall quality of life evaluated on the basis of the EUROQUOL questionnaire(3months, 12 months, 24 months)
  • testing for the prognostic factors of the onset post thrombotic syndrome and comparison of the onset kinetics of post thrombotic syndrome(24 months)
  • superiority of 25 mm Hg for constraints related to compression and chronic venous insufficiency quality of life (CIVIQ)(3 months, 12 months, 24 months)
  • non inferiority of 25 mm Hg for the comparative evaluation of the symptomatic effect of short-term compression (pain, sensation of oedema) form baseline to 3 months(3 months)
  • sensitivity analysis of primary endpoint excluding patients with a differential diagnosis can explain a Villalta score ≥ 5(24 months)

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (86)

Loading locations...

相似试验